MacroGenics | MGNX - Cost Of Sales


MacroGenics reported $10.12M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Amgen USD 1.79B 128M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Daiichi Sankyo JPY 118.28B 37.7B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Genmab DKK 81M 23M Dec/2025
Geron USD 1.31M 263K Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
J&J USD 7.97B 689M Dec/2025
Karyopharm Therapeutics USD 37.43M 2.41M Sep/2024
MacroGenics USD 10.12M 34.18M Dec/2025
Merck USD 3.32B 531M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Xencor USD 61.66M 50.95M Jun/2025